Immune Corrective Role of Statin Therapy in Patients with Chronic Obstructive Pulmonary Disease and Metabolic Syndrome
Svitlana Bychkova, Nina Bychkova
Chronic obstructive pulmonary disease (COPD) and cardiovascular diseases are considered as the leading causes of death and mortality in developed countries, the clinical significance of which increases progressively as far as the aging of population. in recent decades was formed COPD in a combination with metabolic syndrome (MS), which is another global disease of civilization and progress, which was a blend of overweight or obesity with hypertension, lipid and carbohydrate metabolism and diabetes. To correct the main manifestations of dyslipidemia as a major component of MS has been successfully using the statins all over the world. The aim of current study was to determine the effect of atorvastatin on parameters of cellular and humoral immune system and the functional activity of immune cells in patients with COPD, combined with MS. The study involved 43 patients with stage I COPD and presence of the metabolic syndrome and 75 patients with stage II COPD and metabolic syndrome. All patients were evaluated by indicators of immune status, which included the tests of I and II levels as required by the Memorandum of WHO. We established the immune-corrective role of statins (atorvastatin) in the treatment of patients with COPD, combined with MS, which is the presence of anti-inflammatory action, reducing the symptoms of autoimmune disorders, reducing the relative content of activated lymphocyte subpopulations and elimination of imbalance of the immune complexes.
How to cite this article:
Svitlana Bychkova, Nina Bychkova. Immune Corrective Role of Statin Therapy in Patients with Chronic Obstructive Pulmonary Disease and Metabolic Syndrome. Pharma Innovation 2013;2(8):33-38.